Author(s)

Xiaomo Li, Zhuoyan Wu, Yumeng Xie

Corresponding Author

Xiaomo Li

ABSTRACT

Currently, checkpoint inhibitors, which function by triggering patients’ own T cells to combat tumor, are revolutionizing treatment for various types of cancer. Atezolizumab, a monoclonal antibody targeting PD-L1 proteins, has shown a much lower mortality rate and a significantly longer survival rate, resulting in its being approved as a reliable treatment for TNBC, NSCLC, and bladder cancer, etc. However, there still exists immune-related adverse events that may affect patients’ recovery in different ways and ought to be carefully assessed. This review mainly focused on analyzing the efficacy of atezolizumab in different stages for the treatment of TNBC, NSCLC, and bladder cancer.

KEYWORDS

PD-1/PD-L1 pathway, atezolizumab, TNBC, NSCLC, bladder cancer